Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073238 | 0.76 | GPR3 (0.39) | GPR3LMNAEGFR | |
| SCHEMBL4574523 | 0.74 | RAB9A (0.42) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL6707380 | 0.74 | CYP1A2 (0.36) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL299834 | 0.73 | NPC1 (0.42) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL30198446 | 0.73 | CYP1A2 (0.60) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL1672650 | 0.73 | CYP1A2 (0.60) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL30527184 | 0.73 | CYP1A2 (0.60) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL13649235 | 0.72 | CYP1A2 (0.61) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL17376382 | 0.72 | CYP1A2 (0.49) | CYP1A2MAPTNPC1RAB9AGPR3 | |
| SCHEMBL28183808 | 0.71 | CYP1A2 (0.70) | CYP1A2MAPTNPC1RAB9AGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777441-B2 | FOR THERAPY AND PROPHYLAXIS | EMORY UNIVERSITY | 2004-08-17 | — | — | US | claimed |
| EP-0432040-B2 | Heterocyclic derivatives of acylaminothiazole, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1997-12-17 | — | — | EP | claimed |
| CN-118109145-A | Adhesive composition, adhesive layer, polarizing plate with adhesive layer, and display device | 住友化学株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-117915677-A | Organic light emitting device | 三星显示有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114026097-B | Substituted pyrazoloquinazolinone compounds and uses thereof | 上海瑛派药业有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117062455-A | Organic light emitting device and electronic apparatus including the same | 三星显示有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3946607-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206000-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (CN) | 2020-10-08 | — | — | WO | disclosed |
| EP-3068752-A1 | AMINE SALTS OF A PROSTACYCLIN ANALOG | Cayman Chemical Company Incorporated (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073314-A1 | AMINE SALTS OF A PROSTACYCLIN ANALOG | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2015-05-21 | — | — | WO | disclosed |
| EP-2702043-A1 | INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE | Exelixis, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-0980357-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-23 | — | — | EP | disclosed |
| US-6004979-A | ANGIOTENSIN II INHIBITORS; 4-((CARBOXY)ARYLOXY)-QUINOLINE DERIVATIVES | HOECHST MARION ROUSSEL (FR) | 1999-12-21 | — | — | US | disclosed |
| WO-1998050363-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| US-5817674-A | ANTIOTENSIN II RECEPTOR ANTAGONISTS | ROUSSEL UCLAF (FR) | 1998-10-06 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CYP1A2 1864/4885MAPT 56/4885NPC1 429/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | CYP1A2 2269/4885MAPT 2166/4885NPC1 626/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | CYP1A2 4792/4885MAPT 4376/4885NPC1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.